TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3639930

Group type: EXPERIMENTAL
Intervention: Infant formula samples
Number of subjects: 95

Group type: COMPARATOR
Intervention: No infant formula samples (Control)
Number of subjects: 95
Study: 31912937

Group type: EXPERIMENTAL
Intervention: Milligan's operation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ferguson's operation
Number of subjects: 151
Study: 30342503

Group type: EXPERIMENTAL
Intervention: Educational program related to older people (intervention)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 124
Study: 27538992

Group type: EXPERIMENTAL
Intervention: Unicortical plate and screw fixation
Number of subjects: 315

Group type: COMPARATOR
Intervention: Bicortical plate and screw fixation
Number of subjects: 315
Study: 24200256

Group type: EXPERIMENTAL
Intervention: Integrated school-wide program focusing on foods and beverages, physical education, classroom-based behavior change and education, and social marketing communication and promotional campaigns.
Number of subjects: 4603

Group type: COMPARATOR
Intervention: Control group (21 schools, 2296 students).
Number of subjects: 4603
Study: 22013105

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily
Number of subjects: 24
Study: 20510523

Group type: EXPERIMENTAL
Intervention: High exposure group (≥500 mg/week)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Moderate exposure group (250-499 mg/week)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Zero-low exposure group (0-249 mg/week)
Number of subjects: 321
Study: 18479659

Group type: EXPERIMENTAL
Intervention: 1,000 AU/week
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 3,000 AU/week
Number of subjects: 65

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SLIT groups
Number of subjects: 65
Study: 20031797

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560
Study: 15106805

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 242

Group type: COMPARATOR
Intervention: Coamilozide
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Nifedipine and Coamilozide
Number of subjects: 242
Study: 11372922

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) injections via percutaneous posterior‐lateral approach
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox) injections via transnasal fiberoptic approach
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 15
Study: 9425975

Group type: EXPERIMENTAL
Intervention: L2 group (injection at the second lumbar vertebra)
Number of subjects: 30

Group type: COMPARATOR
Intervention: L4 group (injection at the fourth lumbar vertebra)
Number of subjects: 30
Study: 8276982

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen daily for 14 days in 4 divided doses
Number of subjects: 17

Group type: COMPARATOR
Intervention: No drug regime (control group)
Number of subjects: 17
Study: 3520384

Group type: EXPERIMENTAL
Intervention: IV dihydroergotamine (DHE) and metoclopramide every 8 hours
Number of subjects: 109

Group type: COMPARATOR
Intervention: Diazepam intravenously every 8 hours
Number of subjects: 109
Study: 31879077

Group type: EXPERIMENTAL
Intervention: Protein supplementation (20-g protein-rich supplement)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbohydrate supplementation (20-g calorie-matched carbohydrate-rich supplement)
Number of subjects: 20
Study: 30700175

Group type: EXPERIMENTAL
Intervention: GnRHa 0.1 mg subcutaneous injection on day 3 after embryo transfer (ET)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 868
Study: 28100402

Group type: EXPERIMENTAL
Intervention: Late surfactant and inhaled nitric oxide
Number of subjects: 450

Group type: COMPARATOR
Intervention: Inhaled nitric oxide alone (control)
Number of subjects: 450
Study: 26337394

Group type: EXPERIMENTAL
Intervention: Day Camp Intervention Arm (DCIA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard Intervention Arm (SIA)
Number of subjects: 115
Study: 23382325

Group type: EXPERIMENTAL
Intervention: PulsePen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: A-Pulse
Number of subjects: 66

Group type: COMPARATOR
Intervention: SphygmoCor
Number of subjects: 66

Group type: COMPARATOR
Intervention: SphygmoCor and PulsePen
Number of subjects: 66
Study: 22134568

Group type: EXPERIMENTAL
Intervention: Cryotherapy (up to 10 lesions per session, up to 4 sessions, every 3 months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Imiquimod (3-times-per-week for 3-4 weeks, up to 2 courses)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 71
Study: 19461553

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Exercise and Diet intervention
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy Lifestyle Control group
Number of subjects: 316

Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 316

Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 316
Study: 18402286

Group type: EXPERIMENTAL
Intervention: Olprinone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 30
Study: 15614026

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 97

Group type: COMPARATOR
Intervention: Irbesartan and Atenolol
Number of subjects: 97
Study: 11724449

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (n=12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n=6)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Clinically active MS patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Clinically stable MS patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Longitudinal study of active MS patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active exacerbations in MS patients
Number of subjects: 26
Study: 9219786

Group type: EXPERIMENTAL
Intervention: Lansoprazole with norfloxacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omeprazole with norfloxacin
Number of subjects: 50
Study: 8432141

Group type: EXPERIMENTAL
Intervention: Inhaled amiloride
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2462444

Group type: EXPERIMENTAL
Intervention: Untreated Dacron aortic bifurcation graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gelatin impregnated Dacron aortic bifurcation graft
Number of subjects: 20
Study: 29862617

Group type: EXPERIMENTAL
Intervention: Trelagliptin 100 mg with insulin (A/A group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo with insulin (P/A group)
Number of subjects: 240
Study: 26887502

Group type: EXPERIMENTAL
Intervention: Beverage containing 55 mg BTP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control beverage without BTP
Number of subjects: 0
Study: 25590055

Group type: EXPERIMENTAL
Intervention: Human placental extract (HPE)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (LE–FAD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 194
Study: 23241332

Group type: EXPERIMENTAL
Intervention: Dance group (n = 15) - cognitive-motor exercise program with dance video gaming, 12 weeks, twice weekly.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n = 16) - strength and balance exercises only, 12 weeks, twice weekly.
Number of subjects: 31
Study: 20375742

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 18515185

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine 1 mg over 24 h (n=115)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine 2 mg over 24 h (n=112)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine 3 mg over 24 h (n=114)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo (n=117)
Number of subjects: 458
Study: 15696321

Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg) after 8 hours of abstinence
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg) after 4 hours of abstinence
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 11872051

Group type: EXPERIMENTAL
Intervention: Suturing of flaps with no drain
Number of subjects: 375

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 375
Study: 10534633

Group type: EXPERIMENTAL
Intervention: 5% minoxidil
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study: 7485340

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin daily
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 682
Study: 2083805

Group type: EXPERIMENTAL
Intervention: ECG with positive T wave in V1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2-variable model (positive T wave in V1 + R/S ratio >= 1 in V1-V2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3-variable model (+ R wave duration in V1-V2 >= 0.04 sec)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2D echocardiography with pertinent dyssynergy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Standard ECG
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2D echocardiography
Number of subjects: 64
Study: 386118

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Warfarin therapy (closely regulated)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no antiplatelet or anticoagulant therapy)
Number of subjects: 50
Study: 30551792

Group type: EXPERIMENTAL
Intervention: ALGOS brief contact intervention (BCI)
Number of subjects: 987

Group type: COMPARATOR
Intervention: Control group (no BCI)
Number of subjects: 987
Study: 27402095

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic middle pancreatectomy (RA-MP)
Number of subjects: 100
Study: 25536308

Group type: EXPERIMENTAL
Intervention: ABThera
Number of subjects: 45

Group type: COMPARATOR
Intervention: Barker's vacuum pack
Number of subjects: 45
Study: 24565455

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study: 21471490

Group type: EXPERIMENTAL
Intervention: Pay-for-performance hospitals
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pay-for-performance hospitals with larger bonuses
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pay-for-performance hospitals that were well financed
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pay-for-performance hospitals in less competitive markets
Number of subjects: 260
Study: 19448382

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Exercise-Vitamin (EV)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vitamin (V)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 57
Study: 17659736

Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 108

Group type: COMPARATOR
Intervention: No-drain group
Number of subjects: 108
Study: 14765044

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.10 microg kg(‐1) bolus 30 minutes before end of surgery
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 96
Study: 11211903

Group type: EXPERIMENTAL
Intervention: Propranolol (30 mg, administered orally once daily at 19:00 h for 14 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (administered orally once daily at 19:00 h for 14 days)
Number of subjects: 14
Study: 9640149

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane or Thiopental
Number of subjects: 40
Study: 7927544

Group type: EXPERIMENTAL
Intervention: REmbIZ3 (rifampicin, ethambutol, isoniazid, pyrazinamide together in a single dose thrice weekly)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: REmb3IZ3alt (rifampicin, ethambutol on one day and isoniazid, pyrazinamide on the next day)
Number of subjects: 49
Study: 2671282

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy and adjuvant doxorubicin and cyclophosphamide chemotherapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy and chemotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone
Number of subjects: 88
Study: 793778

Group type: EXPERIMENTAL
Intervention: 100 mg suloctidil t.i.d.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 mg dihydroergotoxine methylate t.i.d.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30919901

Group type: EXPERIMENTAL
Intervention: Dietary acid load (measured by net endogenous acid production, NEAP)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Higher levels of identified metabolites
Number of subjects: 1045
Study: 29317269

Group type: EXPERIMENTAL
Intervention: 0.025-inch guidewire
Number of subjects: 710

Group type: COMPARATOR
Intervention: 0.035-inch guidewire
Number of subjects: 710
Study: 28475201

Group type: EXPERIMENTAL
Intervention: Sensor-based balance training (4 weeks, twice a week) with real-time visual/audio feedback from wearable sensors.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group received no training.
Number of subjects: 22
Study: 24590363

Group type: EXPERIMENTAL
Intervention: Prototype blood test for vCJD
Number of subjects: 5000
Study: 22841358

Group type: EXPERIMENTAL
Intervention: Supervised exercise training for claudication
Number of subjects: 38
Study: 19834348

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (SUPP) - 400 mg caffeine, 66.7 mg capsicum extract, 10 mg bioperine, 40 mg niacin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLAC) - microcrystalline cellulose
Number of subjects: 21
Study: 17647311

Group type: EXPERIMENTAL
Intervention: Radon baths and transcranial magnetotherapy
Number of subjects: 0
Study: 16096896

Group type: EXPERIMENTAL
Intervention: IV ampicillin (100 mg/kg/day divided every 6 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV ampicillin plus IV gentamicin (5 mg/kg as a single daily dose)
Number of subjects: 40
Study: 12807387

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Topiramate 600 mg/day
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Topiramate 800 mg/day
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study: 10713874

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (1 mg kg‐1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms kg‐1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combination of droperidol (15 micrograms kg‐1) + dimenhydrinate (1 mg kg‐1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: COMPARATOR
Intervention: All treatment groups compared to placebo
Number of subjects: 140
Study: 7555612

Group type: EXPERIMENTAL
Intervention: L-lysine-L-arginine combination (lisargin)
Number of subjects: 0
Study: 1932647

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 29
Study: 7335762

Group type: EXPERIMENTAL
Intervention: Indobufen (200 mg b.i.d. by oral route)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6238923

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30794364

Group type: EXPERIMENTAL
Intervention: Natural regimen (NR) consisting of a cleanser with natural oils, beeswax, and witch hazel, and day and night creams with natural oils, glycerin, and botanical anti-inflammatories.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Synthetic regimen (CR) consisting of a cetyl alcohol, sodium lauryl sulphate-containing cleanser, and glycerin, polyisobutene-containing lotion.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Natural regimen (NR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Synthetic regimen (CR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both regimens (NR and CR)
Number of subjects: 80
Study: 29564752

Group type: EXPERIMENTAL
Intervention: Culturally adapted low-intensity variant of the Triple P-Positive Parenting Program (Te Whānau Pou Toru)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 70
Study: 26842716

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 80

Group type: COMPARATOR
Intervention: CICVC
Number of subjects: 80
Study: 25011730

Group type: EXPERIMENTAL
Intervention: computerised CBT (cCBT) using OCFighter, an internet-delivered OCD treatment package
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: guided self-help (GSH) using a book
Number of subjects: 0
Study: 22362228

Group type: EXPERIMENTAL
Intervention: Mesoglycan (100 mg/day for 6 months)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 20976505

Group type: EXPERIMENTAL
Intervention: Fast injection speed (mean 0.38 ml/s)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Slow injection speed (0.05 ml/s over 40 s)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fast injection speed
Number of subjects: 56

Group type: COMPARATOR
Intervention: Slow injection speed
Number of subjects: 56
Study: 16774821

Group type: EXPERIMENTAL
Intervention: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with volume-controlled (VC) ventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with pressure-support (PS) ventilation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 16225925

Group type: EXPERIMENTAL
Intervention: Bandage soft contact lens (BSCL) application
Number of subjects: 100
Study: 12730756

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily (Once-a-Week study)
Number of subjects: 485
Study: 10407249

Group type: EXPERIMENTAL
Intervention: Proposed test for unobserved covariates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logrank test
Number of subjects: 0
Study: 8685751

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA), n = 19
Number of subjects: 57

Group type: COMPARATOR
Intervention: Open appendectomy (OA), n = 18
Number of subjects: 57
Study: 1833839

Group type: EXPERIMENTAL
Intervention: Dacron graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: PTFE graft
Number of subjects: 25
Study: 6125288

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 8
Study: 31533686

Group type: EXPERIMENTAL
Intervention: Walk this Way (WTW) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 40
Study: 28401352

Group type: EXPERIMENTAL
Intervention: Provisional-FKI
Number of subjects: 113

Group type: COMPARATOR
Intervention: Routine-FKI
Number of subjects: 113
Study: 24886871

Group type: EXPERIMENTAL
Intervention: Single freeze with N2O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single freeze with CO2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double freeze with N2O
Number of subjects: 60
Study: 23822518

Group type: EXPERIMENTAL
Intervention: Probiotics (Ecologic®Barrier)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21795429

Group type: EXPERIMENTAL
Intervention: Brown Rice (BR)
Number of subjects: 202

Group type: COMPARATOR
Intervention: White Rice (WR)
Number of subjects: 202
Study: 19362230

Group type: EXPERIMENTAL
Intervention: Lumbar spine manipulation (experimental group, n = 13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Side-lying control position (control group, n = 14)
Number of subjects: 27
Study: 17531660

Group type: EXPERIMENTAL
Intervention: Defer group (n=91)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Perform group (n=90)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Reference group (n=144)
Number of subjects: 325
Study: 15465985

Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment of residual symptoms (supplemented by lifestyle modification and well-being therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 40
Study: 11176319

Group type: EXPERIMENTAL
Intervention: 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (nonimmunized chicken preparation)
Number of subjects: 79
Study: 10626096

Group type: EXPERIMENTAL
Intervention: mianserin 15 mg/d for 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 16
Study: 7589820

Group type: EXPERIMENTAL
Intervention: Intensive therapy with sulfonylurea or insulin
Number of subjects: 4209

Group type: COMPARATOR
Intervention: Conventional therapy primarily with diet
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Intensive therapy with metformin
Number of subjects: 4209

Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Intensive therapy compared with conventional therapy
Number of subjects: 4209